UFIS-SWE-IG
0.1.0 - ci-build
UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions
<AdministrableProductDefinition xmlns="http://hl7.org/fhir">
<id value="TPTDteva-2080-Solution-SE-IS-APD"/>
<meta>
<profile
value="http://unicom-project.eu/fhir/StructureDefinition/PPLAdministrableProductDefinition"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: AdministrableProductDefinition TPTDteva-2080-Solution-SE-IS-APD</b></p><a name="TPTDteva-2080-Solution-SE-IS-APD"> </a><a name="hcTPTDteva-2080-Solution-SE-IS-APD"> </a><a name="hcTPTDteva-2080-Solution-SE-IS-APD-en-US"> </a><p><b>status</b>: Active</p><p><b>formOf</b>: <a href="MedicinalProductDefinition-TPTDteva-2080-Solution-SE-IS-MPD.html">MedicinalProductDefinition: identifier = http://ema.europa.eu/fhir/mpId#SE-100001594-00053004,http://ema.europa.eu/fhir/eurdId#2903; domain = Human use; status = Current; combinedPharmaceuticalDoseForm = Solution for injection in pre-filled pen; indication = Teriparatide Teva är avsett för vuxna. Behandling av osteoporos hos postmenopausala kvinnor och hos män med ökad risk för frakturer (se avsnitt 5.1). Incidensen vertebrala och icke-vertebrala frakturer reduceras signifikant hos postmenopausala kvinnor men detta har ej visats för höftfrakturer. Behandling av osteoporos i samband med kronisk systemisk glukokortikoidbehandling hos kvinnor och män med ökad risk för frakturer (se avsnitt 5.1).; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = H05AA02</a></p><p><b>administrableDoseForm</b>: <span title="Codes:{https://spor.ema.europa.eu/v1/lists/200000000004 100000073863}">Solution for injection</span></p><p><b>producedFrom</b>: <a href="ManufacturedItemDefinition-TPTDteva-2080-Solution-SE-IS-MID.html">ManufacturedItemDefinition: status = active; manufacturedDoseForm = Solution for injection in pre-filled pen; unitOfPresentation = Pen</a></p><h3>RouteOfAdministrations</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://spor.ema.europa.eu/v1/lists/100000073345 100000073633}">Subcutaneous use</span></td></tr></table></div>
</text>
<status value="active"/>
<formOf>🔗
<reference
value="MedicinalProductDefinition/TPTDteva-2080-Solution-SE-IS-MPD"/>
</formOf>
<administrableDoseForm>
<coding>
<system value="https://spor.ema.europa.eu/v1/lists/200000000004"/>
<code value="100000073863"/>
<display value="Solution for injection"/>
</coding>
</administrableDoseForm>
<producedFrom>🔗
<reference
value="ManufacturedItemDefinition/TPTDteva-2080-Solution-SE-IS-MID"/>
</producedFrom>
<routeOfAdministration>
<code>
<coding>
<system value="https://spor.ema.europa.eu/v1/lists/100000073345"/>
<code value="100000073633"/>
<display value="Subcutaneous use"/>
</coding>
</code>
</routeOfAdministration>
</AdministrableProductDefinition>